|
|
|
|
|
Back to 2014 Annual Meeting Abstracts
Quality of Life after Breast-Conserving Therapy: A Utility Score Assessment Study
Hani Sinno, MD, MEng1, Joshua Vorstenbosch, PhD1, Tassos Dionisopoulos, MD1, Ahmed Ibrahim, M.D.2, Adam Tobias, MD2, Samuel Lin, MD2, Bernard Lee, MD, MBA2.
1McGill University, Montreal, QC, Canada, 2Harvard Medical School/Beth Israel Deaconess Medical Center, Boston, MA, USA.
BACKGROUND:
Lumpectomy followed by radiation, otherwise known as breast-conserving therapy (BCT), has become one of the gold standard treatments for early stage breast cancer. We sought to investigate the health state burden of living with BCT.
METHODS:
Three validated health state preference utility tools were used to objectify living with BCT: visual analogue scale (VAS), time trade-off (TTO), and standard gamble (SG). A prospective sample of the general population and medical students was used to attain these scores.
RESULTS:
Utility scores for living with BCT (VAS: 0.81 ± 0.19, TTO: 0.93 ± 0.10, and SG: 0.92 ± 0.14) in the 103 volunteers were significantly different from the corresponding scores for monocular (0.63 ± 0.19, 0.86 ± 0.14, and 0.86 ± 0.19, respectively) and binocular blindness (0.32 ± 0.18, 0.61 ± 0.25, and 0.62 ± 0.25, respectively). Age, gender, race, education, and income were not statistically significant independent predictors of utility scores.
CONCLUSIONS:
We have performed a health state preference outcome utility assessment of living with BCT. The utility scores in our sample population translated to a willingness to gamble with an 8 percent chance of death and be willing to trade 4.4 years of their existing life-years.
Back to 2014 Annual Meeting Abstracts
|
|
